These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 21393156)

  • 1. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG; Sader HS; Jones RN
    J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
    [No Abstract]   [Full Text] [Related]  

  • 3. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM; Ward KE; LaPlante KL
    Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
    Sader HS; Becker HK; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS; Jones RN; Rossi KL; Rybak MJ
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital].
    Piérard D; Vandenbussche H; Verschraegen I; Lauwers S
    Pathol Biol (Paris); 2004 Oct; 52(8):486-8. PubMed ID: 15465269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.
    Velazquez A; DeRyke CA; Goering R; Hoover V; Wallace MR
    Clin Microbiol Infect; 2013 Dec; 19(12):1169-72. PubMed ID: 23480569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
    Appleman MD; Citron DM
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
    Skiest DJ
    J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB; Saravolatz LD; Husain N
    Int J Antimicrob Agents; 2010 Nov; 36(5):478-80. PubMed ID: 20846830
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
    Nannini E; Murray BE; Arias CA
    Curr Opin Pharmacol; 2010 Oct; 10(5):516-21. PubMed ID: 20598637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate vancomycin susceptibility in a community-associated MRSA clone.
    Graber CJ; Wong MK; Carleton HA; Perdreau-Remington F; Haller BL; Chambers HF
    Emerg Infect Dis; 2007 Mar; 13(3):491-3. PubMed ID: 17552110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.